Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma (Oncotarget (2018) 9 (31264-31277) DOI: 10.18632/oncotarget.25805)

Michal Alon; Rand Arafeh; Joo Sang Lee; Sanna Madan; Shelly Kalaora; Adi Nagler; Tereza Abgarian; Polina Greenberg; Eytan Ruppin; Yardena Samuels

Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma (Oncotarget (2018) 9 (31264-31277) DOI: 10.18632/oncotarget.25805)

Michal Alon, Rand Arafeh, Joo Sang Lee, Sanna Madan, Shelly Kalaora, Adi Nagler, Tereza Abgarian, Polina Greenberg, Eytan Ruppin, Yardena Samuels

Research output: Contribution to journal › Comment/debate

Abstract

This article has been corrected: The correct Acknowledgments information is given below: ACKNOWLEDGMENTS The authors thank Tamar Ziv and Arie Admon (The Smoler Proteomics Center, Technion, Israel) for the proteomic analysis. The authors also thank Antonella Di Pizio and Masha Y. Niv (The Hebrew University of Jerusalem, Israel) for performing the structural analysis on predicted NF1 cleavage sites. The authors also thank The De Botton Protein Profiling institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science for identifying the proteolytic product of NF1. The work was supported by Minerva Foundation Grant.

Original language	English
Pages (from-to)	1344
Number of pages	1
Journal	Oncotarget
Volume	10
Issue number	13
State	Published - 1 Feb 2019
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{8dd9bbefd5174d71ba3d9daae6cea747,

title = "Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma (Oncotarget (2018) 9 (31264-31277) DOI: 10.18632/oncotarget.25805)",

abstract = "This article has been corrected: The correct Acknowledgments information is given below: ACKNOWLEDGMENTS The authors thank Tamar Ziv and Arie Admon (The Smoler Proteomics Center, Technion, Israel) for the proteomic analysis. The authors also thank Antonella Di Pizio and Masha Y. Niv (The Hebrew University of Jerusalem, Israel) for performing the structural analysis on predicted NF1 cleavage sites. The authors also thank The De Botton Protein Profiling institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science for identifying the proteolytic product of NF1. The work was supported by Minerva Foundation Grant.",

author = "Michal Alon and Rand Arafeh and Lee, {Joo Sang} and Sanna Madan and Shelly Kalaora and Adi Nagler and Tereza Abgarian and Polina Greenberg and Eytan Ruppin and Yardena Samuels",

note = "Publisher Copyright: {\textcopyright} Alon et al.",

year = "2019",

month = feb,

day = "1",

language = "الإنجليزيّة",

volume = "10",

pages = "1344",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "13",

}

TY - JOUR

T1 - Correction

T2 - CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma (Oncotarget (2018) 9 (31264-31277) DOI: 10.18632/oncotarget.25805)

AU - Alon, Michal

AU - Arafeh, Rand

AU - Lee, Joo Sang

AU - Madan, Sanna

AU - Kalaora, Shelly

AU - Nagler, Adi

AU - Abgarian, Tereza

AU - Greenberg, Polina

AU - Ruppin, Eytan

AU - Samuels, Yardena

PY - 2019/2/1

Y1 - 2019/2/1

N2 - This article has been corrected: The correct Acknowledgments information is given below: ACKNOWLEDGMENTS The authors thank Tamar Ziv and Arie Admon (The Smoler Proteomics Center, Technion, Israel) for the proteomic analysis. The authors also thank Antonella Di Pizio and Masha Y. Niv (The Hebrew University of Jerusalem, Israel) for performing the structural analysis on predicted NF1 cleavage sites. The authors also thank The De Botton Protein Profiling institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science for identifying the proteolytic product of NF1. The work was supported by Minerva Foundation Grant.

AB - This article has been corrected: The correct Acknowledgments information is given below: ACKNOWLEDGMENTS The authors thank Tamar Ziv and Arie Admon (The Smoler Proteomics Center, Technion, Israel) for the proteomic analysis. The authors also thank Antonella Di Pizio and Masha Y. Niv (The Hebrew University of Jerusalem, Israel) for performing the structural analysis on predicted NF1 cleavage sites. The authors also thank The De Botton Protein Profiling institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science for identifying the proteolytic product of NF1. The work was supported by Minerva Foundation Grant.

UR - http://www.scopus.com/inward/record.url?scp=85061565799&partnerID=8YFLogxK

M3 - تعليقَ / نقاش

SN - 1949-2553

VL - 10

SP - 1344

JO - Oncotarget

JF - Oncotarget

IS - 13

ER -

Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma (Oncotarget (2018) 9 (31264-31277) DOI: 10.18632/oncotarget.25805)

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this